COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804

Article view: 35

Article download: 24

IP Journal of Diagnostic Pathology and Oncology


Clinico-pathological co-relation using various immuno-histochemistry markers likeER, PR, HER-2 NEU, CK5/6, EGFR, KI-67 in carcinoma breast


Full Text PDF Share on Facebook Share on Twitter


Research Article

Author Details : Gyanendra S Mittal*, Suraj Manjunath, B Niranjan Naik, Sanjay Deb

Volume : 5, Issue : 1, Year : 2020

Article Page : 30-34


Suggest article by email

Abstract

Introduction: In India, for the year 2012, 144,937 women were newly detected with breast cancer and
70,218 women died of it. For every 2 women newly diagnosed with breast cancer, one lady is dying of it.
The aim of this study is to evaluate clinical parameters and pathological findings including various Immunohistochemistry
(IHC) markers like ER, PR, HER-2 NEU, CK5/6, EGFR, Ki-67 in cases of carcinoma breast
and classify them into molecular classification based on IHC markers and try to correlate them clinically.
Materials and Methods: This prospective, observational study was carried out in 56 patients with early
carcinoma breast (stage-I and stage-II) and IHC evaluation for various markers was done. Data was
analysed by using Molecular Classification, divide them into estrogen positive (luminal HER-2, luminal
A and luminal B) and estrogen negative (Triple negative or basal cell type, HER-2Neu type and normal
breast like phenotype) subtypes. We had correlated this data with parameters like age of the patient, clinical
and pathological staging of the breast carcinoma, presence or absence of nodes and presence or absence of
other IHC parameters.
Results: We used ANOVA-F test to catagories variables and measure the test of significance. On IHC in
Her-2 neu equivocal cases (patients who had two “++” positive points), we performed FISH test. Out of
these 17 equivocal cases, only 3 were positive, 10 were negative and 4 patients did not underwent this test
due to several reasons. Finally, Ki-67 value is significantly high in triple negative and Luminal-B patients.
NPI is also having low ‘P’value, although not reaching the level of significance.
Conclusion: Types of breast carcinoma, which look histologically similar behaves differently in their
clinical presentation and in prognosis. In our study only Ki-67 was correlated with poor prognostic
subtype of molecular classification but no any poor risk of clinical or histological parameter was correlated
significantly with bad prognostic subtype of molecular classification as Luminal-B or triple negative type.
We can say that this molecular classification is different in terms of prognosis in patients with similar
looking clinical and histological parameters.

Keywords: Molecular Clssification, IHC markers, Carcinoma Breast, Triple Negative, Luminal Breast Carcinoma.

Doi : 10.18231/j.jdpo.2020.006

How to cite : Mittal G S, Manjunath S , Naik B N, Deb S, Clinico-pathological co-relation using various immuno-histochemistry markers likeER, PR, HER-2 NEU, CK5/6, EGFR, KI-67 in carcinoma breast. IP J Diagn Pathol Oncol 2020;5(1):30-34

Copyright © 2020 by author(s) and IP J Diagn Pathol Oncol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (creativecommons.org)